ARTICLES BY RONALD W. LANTON III

  • 2 Bills, 1 Goal: Lower Drug Prices Through Biosimilars
    2 Bills, 1 Goal: Lower Drug Prices Through Biosimilars

    Just prior to an election season, it is not surprising to see a few bills emerge as potential silver bullets to solve pressing policy issues. One issue that has consumed the public for several years is drug prices. This article examines two Congressional bills aimed at increasing biosimilar utilization in an effort to lower drug costs.

  • How Would Proposed Congressional Price Control Policies Impact Biosimilars?
    How Would Proposed Congressional Price Control Policies Impact Biosimilars?

     

    Sen. Bernie Sanders has introduced three bills aimed at reducing prescription drug prices, two of potential importance to biosimilar developers. This article discusses these cost-containment policies, as well as two other congressional initiatives to watch.

  • The Current State Of U.S. Biosimilar Policies — An Overview
    The Current State Of U.S. Biosimilar Policies — An Overview

    With the continued policy dialogue on how rising drug costs impact patient access, the theoretical cost savings that biosimilars may offer is intriguing to many policymakers as well as those in the industry. 

Ronald W. Lanton III

Ronald W. Lanton III

Ronald W. Lanton III, Esq., has over 25 years of experience in government affairs on the municipal, state, and federal government levels, with 15 years dedicated to the healthcare sector. He founded the healthcare government affairs and lobbying firm True North Political Solutions and also served as the executive director and head lobbyist at Frier Levitt Government Affairs, where he created a government affairs practice and served as senior counsel for Frier Levitt Law. Lanton is a featured industry speaker on issues such as pharmaceutical safety and healthcare cost containment and has authored numerous articles regarding pharmacy and healthcare law. Currently he is consulting for the healthcare industry. You can reach him at ronlanton3@gmail.com or connect with him on LinkedIn. Lanton is a featured industry speaker on issues such as pharmaceutical safety and healthcare cost containment, and he has authored numerous articles regarding pharmacy and healthcare law. He earned a B.A. from Miami University and a J.D. from The Ohio State University. He is also the chair of the Biologics Committee for the New York Bar Association.